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Abstract Our aim was to compare the effects of an
intermediate acting human insulin (NPH) and a long-acting
insulin analog, insulin glargine, in insulin naı¨ve type 2
diabetes patients, stratified by the type of hyperglycemia
(fasting or postprandial type). Based on different action
profiles, we hypothesized that patients having different
hyperglycemia types would react differently when treated
with these insulins. This is a post hoc analysis of the
Lanmet study data. The Lanmet study was a randomized,
36-week controlled insulin initiation study in type 2 dia-
betes patients. 109 subjects with baseline HbA1c [8.0 %
(64 mmol/mol) completed the study. The patients were
divided into two groups according to fasting glucose
(mmol/l)/HbA1c (%) ratio. Patients with a ratio C1.3 were
defined as having fasting type and those with a ratio \1.3
as having postprandial type hyperglycemia. The main
outcome measures were change in HbA1c and body
weight, and final insulin dose. Independently of insulin
type, compared to patients with postprandial type hyper-
glycemia, those with fasting type hyperglycemia had
2.1 kg/m2 greater initial BMI (p = 0.044), gained 2.0 kg
more weight (p = 0.020, adjusted for baseline BMI
p = 0.035), and had 36 % greater final insulin dose/kg
(p = 0.001). With respect to hyperglycemia type, there
was no difference between NPH and glargine in their
effects on HbA1c. When starting bedtime insulin in type 2
diabetes patients, those with fasting type hyperglycemia are
prone to greater weight gain. Hyperglycemia type does not
help in identifying patients who would benefit specially
from either NPH insulin or insulin glargine.
Keywords Insulin treatment  Insulin analog 
Hyperglycemia type  Body weight increase  Type 2
diabetes
Introduction
Some patients with type 2 diabetes have high fasting values
and only moderately elevated postprandial values (fasting
type hyperglycemia), while others have mainly high post-
prandial glucose concentrations (postprandial type hyper-
glycemia) [1]. This variation may be related to differences
in the pathogenesis of type 2 diabetes between individual
patients [2] and the severity of the metabolic disturbance
[1]. We have previously examined insulin initiation in type
2 diabetes patients with respect to the hyperglycemia type
and concluded that not all poorly controlled type 2 diabetes
patients should automatically be treated with an oral agent
and bedtime insulin, but patients with postprandial type
hyperglycemia might benefit more from treatment with two
daily NPH insulin injections [1]. At the time of the data
collection of that study, long-acting insulin analogs were
not available. Due to its long and steady duration of action,
insulin glargine [4–6] has a better effect than NPH insulin
on postprandial glucose concentrations [7, 8]. On the other
hand, subjects with fasting type hyperglycemia might
benefit relatively more from bedtime NPH insulin as its
action is strong in the early morning hours. Although the
difference in the time action profiles of glargine and NPH
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has been well established, there are no studies examining
whether patients with fasting as compared to postprandial
type hyperglycemia benefit more from NPH than glargine
insulin.
The objective of this retrospective study was to compare
the effect of human NPH insulin and a long-acting insulin
analog glargine in insulin naı¨ve type 2 diabetes patients,
stratified by the type of hyperglycemia. We hypothesized
that patients having fasting type hyperglycemia treated
with NPH insulin or having postprandial type hypergly-
cemia treated with insulin glargine would have a greater
improvement in HbA1c compared with patients having
postprandial type hyperglycemia treated with NPH insulin
or having fasting type hyperglycemia treated with insulin
glargine. Moreover, we wanted to examine whether the
hyperglycemia type is associated with insulin dose and
weight change after insulin initiation.
Methods
Design of the study
The study was a post hoc analysis of the data collected in
the Lanmet study [9]. The original study was performed in
Finland and in the United Kingdom applying note for
guidance CPMP/OCH/135/95. The ethics committees in all
participating sites approved the study. Each patient gave an
informed consent. In that study, 109 type 2 diabetes
patients were randomized to use metformin with either
glargine (60 patients) or NPH insulin (49 patients) as a bed-
time injection. The sulphonylureas were stopped at ran-
domization, but metformin was continued with unchanged
dose throughout the study. According to the protocol, the
insulin dose was aggressively raised until the target value
of fasting plasma glucose (below 5.5 mmol/l) was
achieved. In the present analysis, we divided the 109
type 2 diabetes patients that completed the study into two
groups according to their hyperglycemia type. This was
determined by the fasting plasma glucose/glycosylated
hemoglobin ratio (mmol/l/%) as described previously [1].
Those who had a ratio over or equal to 1.3 (N = 57)
formed the fasting type hyperglycemia group, and those
whose ratio was less than 1.3 formed the postprandial type
hyperglycemia group (N = 52).
Subjects
The study subjects were type 2 diabetes patients treated
with a stable dose (any dose) of sulphonylureas and met-
formin (C1.5 g daily) or metformin alone for at least
3 months prior to screening. Their mean age was 56 years
and diabetes duration 9 years. HbA1c was C8.0% and
fasting plasma glucose C7.0 mmol/l. They were C-peptide
positive (C0.33 nmol/l) and insulin naı¨ve. Patients with
positive GAD antibodies, abnormal safety laboratory tests,
history of alcohol or drug abuse, as well as those using
other antihyperglycemic agents were not included. 109
patients were eligible to participate in the study that lasted
for 36 weeks.
Laboratory methods
HbA1c was measured by high-pressure liquid chromatog-
raphy using the fully automated Glycosylated Hemoglobin
Analyzer System (Bio-Rad, Richmond, CA, USA) trace-
able to the Diabetes Control and Complications Trial ref-
erence method, with a reference range of 4.0–6.0%. Serum
concentrations of C-peptide and GAD antibodies were
determined by RIA. S-ALT activity, high sensitivity CRP,
and serum lipid and lipoproteins were determined by
standard clinical laboratory methods.
Outcome measures
Outcome measures were changes in fasting plasma glu-
cose, HbA1c, and body weight as well as final insulin dose
and occurrence of hypoglycemic events.
Statistical analyses
Two-group comparisons were performed comparing
groups with the two insulin types or comparing groups with
the two types of hyperglycemia. Two-group comparisons
were also performed comparing the effect of the two
insulin preparations within the two hyperglycemia type
groups (Ja¨rjestysmuutos). Four groups were formed
according to hyperglycemia type and insulin preparation
used. Due to statistically significant differences in the
baseline HbA1c and BMI between these groups, compari-
sons were made also adjusting for these variables when
appropriate. Statistical analyses were performed with the
SAS program, version 14 (t test, paired t test, Mann–
Whitney U test, ANOVA, ANOVA of repeated measure-
ments or ANCOVA, when appropriate).
Results
Baseline characteristics of the four groups formed
according to hyperglycemia type (fasting type or post-
prandial type), and insulin type (NPH or glargine) are
shown in Table 1. By definition, baseline fasting glucose
values were higher in fasting type hyperglycemia groups.
HbA1c values did not differ significantly between the
groups. Average metformin dose was similar in all groups,
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and the proportion of patients having a history of sulpho-
nylurea use was comparable between the groups.
Compared to patients with postprandial type hypergly-
cemia, those having fasting type hyperglycemia had sig-
nificantly higher serum triglyceride, hs-CRP, and ALT
concentrations. They also tended to have slightly more
often hypertension (80.7 vs 71.2%), but this difference was
not statistically significant.
In subjects using glargine, there was a statistically sig-
nificantly greater (p = 0.034) decrease of HbA1c in post-
prandial type hyperglycemia group compared with that in
the fasting type hyperglycemia group (Table 2; Fig. 1).
This, however, was no more the case, when the groups
were adjusted for baseline HbA1c (p = 0.489) or baseline
BMI (p = 0.493). In subjects using NPH insulin, there was
a tendency toward a greater decrease in HbA1c in fasting
type hyperglycemia group compared with postprandial
type hyperglycemia group (p = 0.075).
The combined group of patients having fasting type
hyperglycemia and treated with NPH or postprandial type
hyperglycemia treated with glargine had a greater
improvement of glycemia compared to the combined group
with fasting type hyperglycemia treated with glargine or
postprandial type hyperglycemia treated with NPH
(p = 0.046, after adjustment for baseline HbA1c
p = 0.052). However, this difference disappeared after
further adjustment for baseline BMI (p = 0.813).
Baseline BMI of the subjects having fasting type
hyperglycemia was 2.1 kg/m2 greater than that of those
having postprandial type hyperglycemia (p = 0.044). The
weight gain of fasting type hyperglycemia patients during
the study was 2.0 kg greater (p = 0.020; after adjustment
for baseline BMI, p = 0.035) than of those, whose
hyperglycemia was of postprandial type. The weight gain
was not different between patients using NPH or glargine
insulin.
Fasting plasma glucose decreased in all four groups. The
decrease was smaller in both postprandial type hypergly-
cemia groups compared to fasting type hyperglycemia
groups (p \ 0.001). There was no difference (p = 0.667)
in the decrease of fasting glucose between NPH and glar-
gine using patients either within the fasting type or within
the postprandial type group.
Independently of insulin type, the final insulin dose was
on the average 0.77 IU/kg body weight in fasting type
hyperglycemia group but only 0.57 IU/kg in patients with
postprandial type hyperglycemia. This difference was sta-
tistically significant (p = 0.001).
During the first 3 months, NPH insulin treatment was
associated with more hypoglycemic events than glargine
Table 1 Baseline characteristics by hyperglycemia type and insulin preparation













Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Sex (%, M/F) 54/46 64/36 58/42 76/24 67/33 71/29 n.s.
Age (years) 55.9 8.7 57.0 7.7 58.3 8.3 56.6 10.6 57.9 9.2 57.3 9.8 n.s.
BMI (kg/m2) 32.1 4.7 33.5 6.3 32.7 5.4 30.1 5.8 30.7 4.2 30.6 5.0 0.044
Fasting plasma
glucose (mmol/l)
13.8 2.4 14.1 1.8 13.9 2.2 10.6 1.7 10.6 1.6 10.6 1.7 \0.001
HbA1c (%) 9.0 1.2 9.4 1.0 9.1 1.1 9.2 1.0 9.2 1.1 9.2 1.0 n.s.
HbA1c (mmol/mol) 75 13 79 11 76 12 77 11 77 11 77 11 n.s.
fP-Gluc/HbA1c
(mmol/l/%)
1.6 0.3 1.5 0.2 1.5 0.2 1.2 0.1 1.2 0.1 1.2 0.1 \0.001
Metformin dose (g) 2.3 0.5 2.2 0.4 2.2 0.4 2.3 0.4 2.1 0.3 2.2 0.4 n.s.
Sulphonylurea users (%) 77.1 86.4 80.7 80.8 85.2 82.7 n.s.
Hypertension (%)b 74.3 90.9 80.7 64.0 77.8 71.2 n.s.
fP-Chol (mmol/l) 5.07 1.96 4.91 0.90 5.00 1.08 4.73 0.93 5.10 0.92 4.92 0.94 n.s.
fP-HDL-Chol (mmol/l) 1.18 0.35 1.12 0.21 1.16 0.30 1.18 0.23 1.16 0.30 1.17 0.27 n.s.
fP-Trigly (mmol/l)c 2.47 1.28 2.73 1.21 2.57 1.25 2.12 1.48 2.31 1.95 2.22 1.73 0.018
hs-CRP (mg/l)c 4.8 5.9 3.3 3.6 4.2 5.2 2.53 3.4 2.16 2.4 2.3 2.9 0.010
S-ALT (IU/l) 50.6 38.8 46.0 36.3 48.9 37.7 34.6 19.7 35.6 17.0 35.1 18.2 0.019
a p values show the significance of differences between combined groups (Glargine ? NPH) in fasting and postprandial hyperglycemia types
b Antihypertensive medication or systolic blood pressure [140 mmHg or diastolic blood pressure [90 mmHg
c Statistical analysis after logarithmic transformation
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(p = 0.05). This difference between insulin types was not
associated with the type of hyperglycemia and disappeared
with time. When both insulin types were combined, sub-
jects with postprandial type hyperglycemia tended to have
more hypoglycemias (p = 0.055). This difference also
disappeared after the three first months of the study.
Discussion
As far as we know, there is only one previous study on the
initiation of insulin therapy in type 2 diabetes patients taking
into account the type of hyperglycemia [1]. In that study, NPH
insulin given twice daily resulted in postprandial type
hyperglycemia (termed as ‘‘overall hyperglycemia’’ in that
study) patients in a greater decrease in HbA1c compared
with a combination of bedtime NPH ? sulfonylurea or
metformin. In fasting type hyperglycemia patients such an
advantage of NPH insulin twice daily was not observed. The
hypothesis of the present study was that the effects of a long-
acting analog glargine and NPH insulin would be different in
patients that have different hyperglycemia types. In line with
the hypothesis, in unadjusted analysis, a combined group of
patients having fasting type hyperglycemia and treated with
NPH or postprandial type hyperglycemia treated with glar-
gine had a greater improvement of glycemia compared to a
Table 2 Body weight, glucose control, insulin dose, and hypoglycemic events during the trial













Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Body weight (kg)
0 week 94.0 18.1 98.6 22.2 95.8 19.7 90.8 19.5 90.9 13.6 90.9 15.9 n.s.
12 weeks 95.6 18.5 100.2 22.2 97.4 19.9 91.2 19.5 92.2 14.4 92.7 16.4 n.s.
24 weeks 96.7 18.5 102.3 24.1 98.9 20.8 91.8 20.1 92.6 15.1 92.2 16.9 0.069
36 weeks 97.5 19.3 103.5 24.4 99.8 21.4 92.3 18.8 93.3 15.1 92.8 16.8 0.064
D0 versus 36 weeks 3.4 4.9 4.9 5.0 4.0 4.9 1.5 3.4 2.4 4.3 2.0 3.9 0.020
Fasting blood glucose (mmol/l)
0 week 13.8 2.4 14.1 1.8 13.9 2.2 10.7 1.8 10.6 1.5 10.6 1.7 \0.001
12 weeks 6.5 1.4 7.1 2.1 6.7 1.7 6.3 1.6 6.6 2.0 6.4 1.8 n.s.
24 weeks 6.2 1.7 6.7 2.2 6.4 1.9 6.6 1.5 6 1.3 6.3 1.4 n.s.
36 weeks 6.4 1.6 5.9 1.6 6.2 1.6 6.4 2.6 5.9 1.6 6.2 2.2 n.s.
D0 versus 36 weeks -7.4 2.9 -8.2 2.2 -7.7 2.6 -4.2 2.8 -4.7 2.5 -4.5 2.7 \0.001
HbA1c (%)
0 week 9.0 1.2 9.4 1.0 9.1 1.1 9.4 1.1 9.2 1.1 9.2 1.0 n.s.
12 weeks 8.1 1.2 7.9 1.1 8.0 1.1 7.8 1 8.2 1.0 7.9 0.9 n.s.
24 weeks 7.3 1.0 7.2 0.9 7.2 1.0 7.3 1 7.4 0.8 7.3 0.9 n.s.
36 weeks 7.2 0.9 6.9 0.8 7.1 0.9 7.1 1 7.3 1.1 7.2 1.0 n.s.
D0 versus 36 weeks -1.8 1.1 -2.4 0.7 -2.1 1.0 -2.1 1.3 -1.9 1.3 -2.0 1.3 n.s.
HbA1c (mmol/mol)
0 weeks 75 13 79 11 76 12 77 11 77 12 77 11 n.s.
12 weeks 65 13 63 12 64 12 60 9 65 10 63 10 n.s.
24 weeks 56 11 55 10 55 11 55 9 57 10 56 10 n.s.
36 weeks 55 10 52 9 54 10 55 11 57 12 55 11 n.s.
D0 versus 36 weeks -20 13 -26 8 -23 11 -23 14 -20 14 -22 14 n.s.
Insulin dose (U/kg)
36 weeks 0.77 0.40 0.78 0.26 0.78 0.36 0.56 0.29 0.58 0.30 0.57 0.25 0.001
Hypoglycemic events per patient
0–12 weeks 0.6 1.4 1.0 1.2 2.6 2.0 0.055
13–24 weeks 0.9 1.4 1.1 1.4 2.1 1.8 0.100
25–36 weeks 1.2 1.8 1.5 2.2 1.7 1.9 n.s.
0–36 weeks 2.8 4.6 3.5 4.6 6.3 5.7 0.061
a p values show the significance of differences between combined groups (Glargine ? NPH) in fasting and postprandial hyperglycemia types
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combined group of patients with fasting type hyperglycemia
treated with glargine or postprandial type hyperglycemia
treated with NPH (p = 0.046). However, after adjustment for
baseline HbA1c and BMI, there was no more such a difference.
Thus, the two insulin types seem not to differ in their effect on
HbA1c decline with respect to the type of hyperglycemia.
Initiation of insulin therapy is known to cause an
unwanted increase of BMI [10]. We found that hypergly-
cemia type was significantly associated with adiposity:
those who had fasting type hyperglycemia were signifi-
cantly more obese than those with postprandial type
hyperglycemia. Those with fasting hyperglycemia also
gained 2.0 kg more weight after insulin initiation (Fig. 2;
p = 0.020, after adjustment for baseline BMI, p = 0.035).
To achieve a similar glycemic control, they also needed
significantly more insulin.
Compared to patients with postprandial type hypergly-
cemia, patients with fasting type hyperglycemia not only
had significantly higher baseline BMI, but they also had
higher serum triglyceride levels and a non-significant ten-
dency toward higher prevalence of hypertension, i.e., two
components of the metabolic or insulin resistance syn-
drome [10] In accordance with this, fasting type hyper-
glycemia patients also exhibited greater degree of low-
grade inflammation (higher hs-CRP values) known to be
associated with insulin resistance [11]. Moreover, fasting
type hyperglycemia patients had higher serum ALT con-
centration reflecting higher liver fat content known to be
connected with insulin resistance [12]. Finally, the higher
insulin dose needed by these patients supports the idea that
fasting type hyperglycemia patients are more insulin
resistant than postprandial type hyperglycemia patients.
It would be interesting to study whether similar associ-
ations between hyperglycemia type and increase in body
weight are present when starting insulin treatment with
insulin detemir as previous studies have suggested that it
may cause less weight gain than NPH or glargine insulin
after insulin initiation [13–15].
We determined the hyperglycemia type by the fasting
plasma glucose/HbA1c ratio as described previously [1]
Patients with a higher ratio (C1.3) were defined as having
fasting type hyperglycemia, whereas those, whose ratio
was below 1.3, were defined as having postprandial type
hyperglycemia. The value 1.3 was calculated based on the
former diagnostic fasting plasma glucose value 7.8 mmol/l
[16] and upper normal limit of HbA1c 6.0%. One may
argue the use of some other fasting plasma glucose/HbA1c
ratio to distinguish fasting type and postprandial type
hyperglycemia patients. However, the ratio 1.3 resulted in
fasting type and postprandial type hyperglycemia groups of
approximately same size in the present study as it did also
in the previous study [1], allowing relevant statistical
comparisons.
The strength of the present study is that it was based on
a controlled randomized trial, the Lanmet study [9]. Its
limitation was that the number of patients in the four
subgroups is relatively small. The findings on the associ-
ations between hyperglycemia type and adiposity and
weight gain should therefore be confirmed in a study with a
greater number of diabetes patients.
The main message of this study is that the patient’s
glucose profile predicts risk of weight gain, which is a
known problem in starting insulin treatment in type 2
diabetes patients [17, 18]. This profile can be easily cal-
culated from the fasting glucose/HbA1c ratio. Analog
insulin cannot automatically be held preferable to the less
expensive NPH insulin [19].
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Fig. 1 Decrease of HbA1c in patients with fasting or postprandial
type hyperglycemia using glargine or NPH insulin. A Fasting type
glargine, B fasting type NPH, C postprandial type glargine, D post-
prandial type NPH
Fig. 2 Increase of body weight in patients with fasting type or
postprandial type hyperglycemia. Patients using NPH or glargine
insulin are combined in the two hyperglycemia type groups
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